INTRODUCTION: It was aimed to determine the reliability of rapid antibody detection test (RADT) results and compatibility with RT-PCR assay in the screening and control of COVID-19 infection. METHODS: The retrospective study was performed with the permission of the Ministry of Health and the local ethics committee of our hospital. Between May 2020 and August 2021, 624 health staffs laboratory results were recorded. Data processing hospital (HIS) and laboratory information system (LIS) records of our hospital were used as data collection method. The level of agreement between tests was estimated using Cohen's κ index. Statistical analyzes were performed using SPSS open source software. RESULTS: The mean age of the participants in the study was 28,46 ± 2,35. 54% were female (337), 46% (n=287) were male, and they had no additional disease. Both rapid antibody testing and RT-PCR tests were negative in 86% (n=540) of all tests. Two nasopharyngeal specimens were collected from each case to perform the RADT and RT-PCR. 13,6% (n=102) of the included patients had positive RT-PCR results. The RADT detected 84 of the 102 RT-PCR-positive cases and there were no false positive results. Overall sensitivity and specificity were 84,7% and 100%, respectively. Sensitivity was found >95% in symptomatic cases. DISCUSSION AND CONCLUSION: The Weimi Bio-Tech COVID-19 Ag RADT can be useful in screening for COVID-19, especially in cases in the first or second weeks of symptomatic infection.